• Authoritative Certification | DEEPBLUE Medical obtained the

    Company News Aug 31, 2022

    Authoritative Certification | DEEPBLUE Medical obtained the "Certificate of Export Commodity Brand"
    Recently, Anhui Deepblue Medical Technology Co., Ltd. (hereinafter referred to as DEEPBLUE) approved the approval of the China Council for the Promotion of International Trade CCPIT (hereinafter referred to as: CCPIT) evaluation, obtained the "Certificate of Export Commodity Brand", which is the national authority of DEEPBLUE export ability highly affirmed, is the future of the work of DEEPBLUE to further expand the overseas market, improve the international brand awareness and competitiveness of the international market. With the progress of social economy, brand building is particularly important in the process of enterprise development. Brand is an intangible asset of an enterprise, which reflects the economic strength, development level and overall image of an enterprise to a certain extent, and is an advantageous weapon for an enterprise in the fierce market competition. Vigorously implementing the brand strategy can not only help enterprises to establish a good corporate image and reputation, improve the trust of customers, but also help enterprises continue to expand the market, in the competition to occupy the advantage. In recent years, DEEPBLUE has accelerated the pace of participating in global competition and created a series of brands with good reputation, which is not only related to the development of enterprises, but also a strong embodiment of enhancing the comprehensive competitiveness of DEEPBLUE. In 2017, the establishment of the International Department of DEEPBLUE marked the formal entry of DEEPBLUE into the international market. In the process of hard struggle from weak to strong, from point to surface, DEEPBLUE relies on innovative technical strength, timely delivery ability, continuous improvement of after-sales service network and continuous optimization and adjustment of brand layout, adding bricks and tiles to "Deepblue Manufacturing" bit by bit, demonstrating the brand strength of DEEPBLUE. The certificate of export commodity brand is also a "cognitive method" for DEEPBLUE, which enables DEEPBLUE to have an in-depth understanding of the current situation and shortcomings of its own development, point out the direction for further improvement and development of the enterprise, and boost the implementation of the "going out" strategy. In the future, DEEPBLUE will be combined with the Suggestions for improvement of CCPIT, further implement the strategy of brand, comprehensive brand building layout, at the same time uphold the beginner's mind, give full play to accumulate and enterprise innovation advantage, strengthen intellectual property rights achievements transformation and product iteration, perfect the system of the intellectual property rights (ipr) protection, increasing foreign propaganda and comprehensive maintenance brand awareness and reputation, DEEPBLUE will further expand the international market of products and make greater contribution to building a carrier for the health industry.
    View More
  • Hefei Mayor Ge Bin and staff from the Health and Health Commission visited and investigated DEEPBLUE Medical

    Company News Mar 21, 2022

    Hefei Mayor Ge Bin and staff from the Health and Health Commission visited and investigated DEEPBLUE Medical
    On the morning of March 13, 2022, Ge Bin, member of the Standing Committee of the Hefei Municipal Party Committee, Executive Deputy Mayor, and related colleagues from the Health and Health Commission visited Anhui DEEPBLUE Medical Technology Co., Ltd. (hereinafter referred to as "DeepBlue Medical") to investigate and investigate the DEEPBLUE New Coronavirus antigen test Reagent development status. Mr. Zhang Chao, chairman of DEEPBLUE Medical, Ms. Chen Fengling, general manager, and the heads of relevant departments warmly received and accompanied the visit and research. Vice Mayor Ge and his entourage came to DEEPBLUE Medical located in Mingzhu Industrial Park and visited the automation workshop of DEEPBLUE Medical. During the visit, Zhang Chao, Chairman of DEEPBLUE, explained in detail the research and development process, production process and production capacity of the New Coronavirus antigen detection reagent. Afterwards, Chairman Zhang Chao reported to Vice Mayor Ge on the development and production and operation of the New Coronavirus antigen detection reagent under the new situation of DEEPBLUE Medical, and introduced in detail the research and development of the new coronavirus antigen detection reagent and the overseas listing process, and the products in the market. Clinical performance testing of overseas authoritative testing institutions, overseas product registration and export sales. Mayor Ge and his entourage fully affirmed and praised the development of DEEPBLUE Medical, and said that since the evening of March 11, the comprehensive team of the State Council's joint prevention and control mechanism for New coronavirus pneumonia decided to add antigen testing as a supplement on the basis of nucleic acid testing. After organizing and formulating the "New Coronavirus Antigen Detection Application Plan (Trial)", Hefei City is studying and formulating policies to promote the development of medical devices and biopharmaceutical industries, further improving the ability to serve enterprises, continuously optimizing the business environment, and helping enterprises in a timely manner. Solve the problems encountered in the development and provide good services for the development of the enterprise. According to the investigation conducted by Vice Mayor Ge and his delegation, Chairman Zhang Chao said that DEEPBLUE Medical is currently actively promoting the application for the registration certificate of the New Coronavirus antigen test in China, and will continue to innovate and reform in the future, strive to develop and produce better products, and further help The prevention and control of the New Coronavirus epidemic in the province has contributed to the economic development of Hefei City.
    View More
  • DEEPBLUE Coronavirus (COVID-19) antigen detection reagent-saliva has passed CE1434 certification, and its comprehensive strength has been internationally recognized

    Company News Nov 19, 2021

    DEEPBLUE Coronavirus (COVID-19) antigen detection reagent-saliva has passed CE1434 certification, and its comprehensive strength has been internationally recognized
    Anhui Deepblue Medical Technology Co., Ltd. (hereinafter referred to as "Deepblue Medical") has made great achievements in expanding the market recently. Its domestic business is booming, and its foreign trade business is constantly breaking through. In order to better serve the EU market, Deepblue Medical has been deeply engaged in the field of technology research and development. After unremitting efforts, the self-developed novel coronavirus (COVID-19) antigen detection reagent-saliva has successfully obtained the CE1434 certificate on November 10, 2021. Deepblue medical novel coronavirus (COVID-19) antigen detection reagent-saliva successfully obtained the CE1434 certificate. So far, Deepblue Medical has passed CE1434 certification for 3 types of novel coronavirus (COVID-19) products, mainly including novel coronavirus (COVID-19) neutralizing antibody (double antigen sandwich) detection reagents, novel coronavirus (COVID-19) antigen detection reagents -Anterior nose, novel coronavirus (COVID-19) antigen detection reagents-saliva, so far, Deepblue Medical is one of the only IVD companies in China that have obtained three certificates at the same time. Deepblue Medical has a wealth of novel coronavirus products and detection solutions. Help global epidemic prevention and control. Deepblue Medical Novel Coronavirus (COVID-19) Antigen Saliva Detection Reagent can quickly detect whether saliva contains nocel coronavirus through saliva samples collected from individuals. It is a very suitable product for personal and family self-testing. It has the following main features Features: Convenient sampling Convenient and fast The results are accurate Since the early stage of the outbreak of the novel coronavirus, Deepblue Medical has integrated its technical strength, and its self-developed series of novel coronavirus (COVID-19) antigen detection reagents have been verified by multiple authoritative institutions: through the British Phase 3B test, the German BfarM special authorization, the Netherlands MINVWS special authorization, etc. The CE1434 certification of the series of novel coronavirus products not only reflects that the product's excellent performance and good user experience have been fully recognized, and meets the needs of the international market, it is also a favorable evidence for Deepblue Medical's influence in the IVD industry, international customer recognition, and international competitiveness. . Deepblue Medical Novel Coronavirus (COVID-19) Antigen Detection Reagent - Saliva Detection Reagent Relying on professional scientific research and innovation strength, Deepblue Medical has independently developed novel coronavirus (COVID-19) antigen saliva detection reagents in a faster and more convenient way to meet the needs of individuals and families for self-testing, allowing more people to cut the infection chain faster , to prevent the risk of virus transmission. In addition, Deep Blue can also provide a full range of rapid detecti...
    View More
  • DEEPBLUE Novel Coronavirus (COVID-19) Neutralizing Antibody (Double Antigen Sandwich) Detection Reagent was awarded CE 1434 Certificate

    Company News Oct 11, 2021

    DEEPBLUE Novel Coronavirus (COVID-19) Neutralizing Antibody (Double Antigen Sandwich) Detection Reagent was awarded CE 1434 Certificate
    On October 8, 2021, the novel coronavirus (COVID-19) neutralizing antibody (double antigen sandwich) detection reagent (colloidal gold method) independently developed by Anhui Deepblue Medical successfully obtained the CE1434 certificate, which meets the relevant EU requirements and market standards. Entry qualification. CE 1434 self-test certification is not only difficult, long-term, and strict, but also a test of comprehensive strength. In July 2021, DeepBlue Medical's novel coronavirus (COVID-19) antigen detection reagent obtained the CE1434 certificate, and the new coronavirus (COVID-19) neutralizing antibody (double-antigen sandwich) detection reagent obtained the CE1434 certificate. The strong recognition of the research and development technology of viral in vitro diagnostic reagents has far-reaching significance for the development of the international market and brand expansion. The novel coronavirus (COVID-19) neutralizing antibody (double-antigen sandwich) detection reagent independently developed by Anhui Deepblue Medical has obtained the CE1434 certificate, which can not only be freely sold in the 31 EU member states, but also bring more convenience to the global anti-epidemic. Check resources. The blessing of the CE1434 certificate also reflects the European market's recognition of the performance and user experience of DeepBlue Medical products, and it is also a high affirmation of the comprehensive strength of DeepBlue Medical. At present, most countries and regions in the world have gradually shifted from nucleic acid testing during the outbreak to neutralizing antibody testing to assess whether immunity is protected. The Deepblue Medical Novel Coronavirus (COVID-19) Neutralizing Antibody (Double Antigen Sandwich) Detection Reagent can simply, quickly and effectively reflect the presence and level of neutralizing antibodies after vaccination, and play a guiding role in the need for booster vaccination. In the future, Deepblue Medical will continue to adhere to the vision of "based on the health industry, give full play to the advantages of science and technology, and build a health industry aircraft carrier", strive to develop better products, and contribute to the global epidemic prevention and control and the evaluation of the immune effect of vaccines!
    View More
  • DEEPBLUE COVID-19 Antigen Test can detect Omicron variants  Evaluated by UCK Poland

    Company News Jun 08, 2022

    DEEPBLUE COVID-19 Antigen Test can detect Omicron variants Evaluated by UCK Poland
    DEEPBLUE COVID-19 Antigen Test can detect Omicron variants  Evaluated by UCK Poland Screenshot of the evaluation report Since the launch of the COVID-19 (SARS-CoV-2) Antigen Test Kit (Colloidal Gold), we have closely followed market changes and needs, and have always paid attention to the feedback of users and distributors after the product has been launched, and continuouslyvalidate our test with new variants. Recently we have completed the Clinical Evaluation on UCK Poland and the results indicates DEEPBLUE Antigen test is able to detect Omicron variants and the sensitivity is very high. Screenshot of the evaluation report
    View More
  • Secretary Yu Aihua visited DEEPBLUE Medical for investigation and research

    Company News Mar 21, 2022

    Secretary Yu Aihua visited DEEPBLUE Medical for investigation and research
    On the afternoon of March 17, Yu Aihua, Member of the Standing Committee of the Provincial Party Committee and Secretary of the Municipal Party Committee, went to Hefei High-tech Zone to preach the spirit of the National Two Sessions, investigate the biopharmaceutical industry and grass-roots party building work, and coordinate on-site to help enterprises solve problems. Wu Lihua, director of the Provincial Drug Administration, and city leaders Shan Hu and Song Daojun attended the ceremony. Ms. Chen Fengling, general manager of DEEPBLUE Medical, and the heads of relevant departments warmly received and accompanied the visit and research.     Secretary Yu expressed strong interest in the New Coronavirus series testing products of different languages and specifications displayed by DEEPBUE Medical. Ms. Chen Fengling, general manager of DEEPBLUE Medical, introduced the self-developed New Coronavirus antigen detection reagents to Secretary Yu and his party by taking the product types and usage methods as the starting point. Secretary Yu fully affirmed and praised the development of DEEPBLUE Medical. After learning about the production and operation of DEEPBUE Medical in detail and experiencing the products on site, Secretary Yu Aihua attached great importance to discussing the trial of the New Coronavirus antigen product in Hefei with relevant departments on the spot, and requested the development and reform, Departments such as economics and information technology, science and technology and other departments will send personnel to station to help enterprises carry out registration application work. Ms. Chen Fengling, general manager of DEEPBLUE Medical, expressed her heartfelt thanks to the leaders of Secretary Yu and his party for their concern and support, and said that she would actively cooperate with relevant departments to complete the submission of application materials for the domestic listing registration certificate, promote the development of local medical and health services at a higher level, and serve the current severe epidemic situation. Contribute scientific research to the situation.
    View More
  • DEEPBLUE Medical Participates in Epidemic Prevention and Control

    Company News Mar 17, 2022

    DEEPBLUE Medical Participates in Epidemic Prevention and Control
    As a responsible and responsible enterprise, DEEPBLUE Medical has been actively repaying the society and continuously fulfilling its corporate citizenship responsibilities. DEEPBLUE Medical has been actively practicing corporate social responsibility for a long time, making continuous efforts in multiple dimensions, focusing on poverty alleviation, education, community, health and other directions, and integrating the core advantages and responsibilities of the enterprise into public welfare and charity. In the spring of 2020, a sudden epidemic disrupted people's lives and touched everyone's heart. Responsible enterprises and caring people from all walks of life have contributed to the prevention and control of the epidemic, and made concerted efforts with all the "guardians" who are fighting on the front line through various forms of donations to fight the epidemic. Bits of little love converge into a stream of warmth that warms people's hearts. In the fight against the epidemic, DEEPBLUE Medical continues to have caring tributaries to join in this "battle" to do their part to fight the epidemic. 1.Donate to Hong Kong On February 21, 2022, the Spring Festival was supposed to be full of flavor, but Hong Kong, China was shrouded in a severe pneumonia epidemic. Ms. Chen Fengling, general manager of DEEPBLUE Medical, actively fulfilled her social responsibilities, gathered strengths in the field to give full play to the industry's strengths, organized the company to donate 20 boxes of COVID-19 antigen front nose self-testing reagents to Hong Kong, and received them from the community in Hong Kong on March 10. Thank you letter from Anti-epidemic Connection. 2.Donate to King's College London In March 2020, DEEPBLUE Medical donated 10,000 SARS-CoV-2 (IgG/IgM) antibody detection kits to King's College London through Peking University HSBC Business School, and received a letter from Mr. Robert Lechler, Senior Vice President of King's College, UK. Thank you letter, the letter said: "One World, One Fight". DEEPBLUE Medical is proud to join hands with the United Kingdom to fight the epidemic, and is even more proud to receive a letter of thanks from Mr. Robert Lechler. 3.Donate to some schools in the province DEEPBLUE Medical donated hand sanitizer gel to Hefei High-tech Zone for use in school resumption. Donated hand sanitizer gel to the Feixi County Yandian Township Special Needs Support Center, Anhui Red Cross Fraternity School, Huangshan Jinchuan Middle School and Taihu Shahe Middle School for epidemic prevention and control. Deep Blue Medical cares about the elderly and children, and the elderly care center and school work together to fight the "epidemic". 4.Help Wuhan Epidemic Prevention and Control At the beginning of 2020, the new crown pneumonia epidemic broke out in Wuhan, Hubei Province for the first time. DEEPBLUE Medical responded quickly and started the donation process as soon as possible to make targeted donations to Wuhan Union Hospital in ...
    View More
  • DEEPBLUE Medical donated COVID-19 antigen detection kit to help Hefei fight the epidemic

    Company News Mar 19, 2022

    DEEPBLUE Medical donated COVID-19 antigen detection kit to help Hefei fight the epidemic
    At present, the situation of at home and abroad is still severe, and the number of new cases continues to rise, which has a serious impact on the lives and health of the people. In the face of the current epidemic prevention situation, DEEPBLUE Medical actively responded to the donation ceremony of COVID-19 antigen detection kit organized by the Hefei Municipal Government, donated 2 million copies of COVID-19 antigen detection kit to the Hefei Red Cross Society, and explained the responsibility of the enterprise with practical actions with responsibility. The donated products are tested by self-collected nasal tip swabs. The operation is simple, and the test results can be obtained in 15 minutes. It is effective for the detection of various mutant strains such as Delta and Omicron, and can be widely used in various types of viruses. Scenarios, such as airports, homes, schools, communities, etc., can alleviate the limitations caused by nucleic acid detection capabilities and can be used as a powerful supplement to nucleic acid detection. This time, DEEPBLUE Medical helped the county and district governments in Hefei City to prevent and control the epidemic by way of free donations, and no sales were carried out. For the convenience of citizens, the donated COVID-19 antigen detection kit are also printed in both Chinese and English. It is reported that in the next step, the Hefei Red Cross Society will distribute the batch of loving COVID-19 antigen detection kit reagents to all units, counties and districts as soon as possible in accordance with the unified arrangement of the Municipal Epidemic Prevention and Control Emergency Headquarters. Hefei citizens can pass the test on their own. This product performs home self-testing, which provides a strong guarantee for the rapid screening needs of large-scale people and helps Hefei fight the epidemic. Since the outbreak of COVID-19 antigen detection kit, DEEPBLUE Medical, as an in vitro diagnostic reagent manufacturer, has shouldered the social responsibility of anti-epidemic and epidemic prevention. At present, DEEPBLUE Medical provides self-developed COVID-19 series detection kits, which can meet different application scenarios of new crown virus rapid detection. DEEPBLUE Medical's Covid-19 antigen detection kits have been exported to 50 countries and regions around the world, and have been registered in more than 30 countries around the world, and the number of COVID-19 series product registration certificates has reached 95. DEEPBLUE Medical will continue to pay close attention to the needs of epidemic prevention and control, and fully support and effectively respond to the epidemic. I believe that with the joint support of all forces in the whole society, we will surely be able to win the battle against the epidemic.
    View More
1 2 3

A total of 3 pages

SEND A MESSAGE
If you have questions or suggestions,please leave us a message,we will reply you as soon as we can!
top
Leave A Message
Leave A Message
If you have questions or suggestions,please leave us a message,we will reply you as soon as we can!

Home

Product